Tags

Type your tag names separated by a space and hit enter

ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring: A systematic review and meta-analysis.
Ann Allergy Asthma Immunol 2019; 122(3):302-313.e2AA

Abstract

BACKGROUND

Allergic diseases have increased worldwide in the last 2 decades, with children suffering the highest burden of the condition. The ω-3 long-chain poly-unsaturated fatty acid (LCPUFA) possesses anti-inflammatory properties that could lead to a reduction in inflammatory mediators in allergies.

OBJECTIVE

A systematic review and meta-analysis of the most recent follow-ups of randomized clinical trials (RCTs) was conducted to assess the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on allergic outcomes in offspring.

METHODS

The RCTs with a minimum of 1-month follow-up post gestation were eligible for inclusion. The CENTRAL, MEDLINE, SCOPUS, WHO's International Clinical Trials Register, E-theses, and Web of Science databases were searched. Study quality was evaluated using the Cochrane Collaboration's risk of bias tool.

RESULTS

Ten RCTs (3,637 children), from 9 unique trials, examined the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on the development of allergic outcomes in offspring. Heterogeneities were seen between the trials in terms of their sample, type, and duration of intervention and follow-up. Pooled estimates showed a significant reduction in childhood "sensitization to egg" (relative risk [RR] = 0.54, 95% confidence interval [CI] = 0.32-0.90), and "sensitization to peanut" (RR = 0.62, 95% CI = 0.40-0.96). No statistical differences were found for other allergic outcomes (eg, eczema, asthma/wheeze).

CONCLUSION

These results suggest that intake of ω-3 LCPUFA started during pregnancy can reduce the risk of sensitization to egg and peanut; however, the evidence is limited because of the small number of studies that contributed to the meta-analyses. The current evidence on the association between supplementation with ω-3 LCPUFA started during pregnancy and allergic outcomes is weak, because of the risk of bias and heterogeneities between studies.

Authors+Show Affiliations

Bournemouth University, Faculty of Health and Social Sciences, United Kingdom; University of Portsmouth School of Health Sciences and Social Work, Portsmouth, Hampshire, United Kingdom. Electronic address: mvahdaninia@bournemouth.ac.uk.University of Portsmouth School of Health Sciences and Social Work, Portsmouth, Hampshire, United Kingdom.University of Portsmouth School of Health Sciences and Social Work, Portsmouth, Hampshire, United Kingdom; University of Brighton, Research and Enterprise, Eastbourne, Hastings, United Kingdom.University of Portsmouth School of Health Sciences and Social Work, Portsmouth, Hampshire, United Kingdom.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30552987

Citation

Vahdaninia, Mariam, et al. "Ω-3 LCPUFA Supplementation During Pregnancy and Risk of Allergic Outcomes or Sensitization in Offspring: a Systematic Review and Meta-analysis." Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, vol. 122, no. 3, 2019, pp. 302-313.e2.
Vahdaninia M, Mackenzie H, Dean T, et al. Ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2019;122(3):302-313.e2.
Vahdaninia, M., Mackenzie, H., Dean, T., & Helps, S. (2019). Ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring: A systematic review and meta-analysis. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 122(3), pp. 302-313.e2. doi:10.1016/j.anai.2018.12.008.
Vahdaninia M, et al. Ω-3 LCPUFA Supplementation During Pregnancy and Risk of Allergic Outcomes or Sensitization in Offspring: a Systematic Review and Meta-analysis. Ann Allergy Asthma Immunol. 2019;122(3):302-313.e2. PubMed PMID: 30552987.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring: A systematic review and meta-analysis. AU - Vahdaninia,Mariam, AU - Mackenzie,Healther, AU - Dean,Taraneh, AU - Helps,Suzannah, Y1 - 2018/12/12/ PY - 2018/08/23/received PY - 2018/11/12/revised PY - 2018/12/06/accepted PY - 2018/12/16/pubmed PY - 2018/12/16/medline PY - 2018/12/16/entrez SP - 302 EP - 313.e2 JF - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology JO - Ann. Allergy Asthma Immunol. VL - 122 IS - 3 N2 - BACKGROUND: Allergic diseases have increased worldwide in the last 2 decades, with children suffering the highest burden of the condition. The ω-3 long-chain poly-unsaturated fatty acid (LCPUFA) possesses anti-inflammatory properties that could lead to a reduction in inflammatory mediators in allergies. OBJECTIVE: A systematic review and meta-analysis of the most recent follow-ups of randomized clinical trials (RCTs) was conducted to assess the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on allergic outcomes in offspring. METHODS: The RCTs with a minimum of 1-month follow-up post gestation were eligible for inclusion. The CENTRAL, MEDLINE, SCOPUS, WHO's International Clinical Trials Register, E-theses, and Web of Science databases were searched. Study quality was evaluated using the Cochrane Collaboration's risk of bias tool. RESULTS: Ten RCTs (3,637 children), from 9 unique trials, examined the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on the development of allergic outcomes in offspring. Heterogeneities were seen between the trials in terms of their sample, type, and duration of intervention and follow-up. Pooled estimates showed a significant reduction in childhood "sensitization to egg" (relative risk [RR] = 0.54, 95% confidence interval [CI] = 0.32-0.90), and "sensitization to peanut" (RR = 0.62, 95% CI = 0.40-0.96). No statistical differences were found for other allergic outcomes (eg, eczema, asthma/wheeze). CONCLUSION: These results suggest that intake of ω-3 LCPUFA started during pregnancy can reduce the risk of sensitization to egg and peanut; however, the evidence is limited because of the small number of studies that contributed to the meta-analyses. The current evidence on the association between supplementation with ω-3 LCPUFA started during pregnancy and allergic outcomes is weak, because of the risk of bias and heterogeneities between studies. SN - 1534-4436 UR - https://www.unboundmedicine.com/medline/citation/30552987/ω_3_LCPUFA_supplementation_during_pregnancy_and_risk_of_allergic_outcomes_or_sensitization_in_offspring:_A_systematic_review_and_meta_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1081-1206(18)31528-X DB - PRIME DP - Unbound Medicine ER -